Genmab — Marts 2021

[StockBull]

Genmab

[StockBull]

MACD nu i køb på 1M, 3M, 6M 12 måneds graf på tradingview så det kan ikke vare længe inden deres TA barometer også indikere køb

[Doublo]

Tak for link Helge. Det er da mærkeligt, at det er så vigtigt at understreger, at den gode nyhed ikke får nogen indflydelse på kursen.

[Helge_LarsenPI-redaktør]

Det er helt almindelig kutyme for analytikere og kommentatorer at vurdere i medierne om hvorvidt en nyhed er kurspåvirkende eller ej
.

[StockBull]

Kursen er p.t TA/Robot styret og ligger og swinger mellem rsi ca.30 til ca.70 på månedsgrafen - 30-40kr swing dagligt

[E_L]

some of you are interested in Major Shareholders; as of March 29, 2021: Artisan Partners Limited Partnership

4,256,006

6.49
%

BlackRock, Inc.

4,789,616

7.30%

[E_L]

Jan van de Winkel , including Warrants Exercisable and RSUs to be Settled Within 60 days 687,862 or

1.05%

[StockBull]

Interesting. Recon its the total they each have in a number of ETFs. Because Blackrock have multiple ETFs that contain Genmab shares

[StockBull]

Blackrocks seems to be increasing so it does not look like its the bigger players thats dumping Genmab

[E_L]

Genmab-boss om sklerose-lancering: Novartis prioriterer os højt

Mens Genmabs partner Novartis med en ny EU-godkendelse til sklerosemidlet Kesimpta nu kan starte lancering i Europa, er processen allerede i fuld gang i USA – og der går det rigtig godt fortæller Genmabs adm. direktør Jan van de Winkel.

(medwatch.dk)

[Helge_LarsenPI-redaktør]

Aktier/middag: Mærsk går frem efter sats på medicin i småsurt marked:
https://www.proinvestor.com/investornyt/673637/aktier-middag-maersk-gar-frem-efter-sats-pa-medicin-i-smasurt-marked

[Doublo]

Pensionisten. nej men den linje man lige ser: Godkendelse som ventet - vil ikke påvirke aktien.

[E_L]

in BioNTech results: BNT311/GEN1046 – Data from a first-in-human Phase 1/2a trial of BNT311 (PD-L1x4-1BB) in 61 heavily pretreated patients with advanced solid tumors was presented at the SITC conference in November 2020. We expect a data update from this trial in the second half of 2021.
BNT312/GEN1042 – We expect first data disclosure from the Phase 1/2a trial of BNT312 in solid tumors in the second half of 2021.

[Bulder]

So nothing at asco.

[E_L]

patience is a virtue....

[E_L]

and by the time it comes, they'll say 'yea, but it was included, right'

[E_L]

Horizon Therapeutics plc to Resupply Market With TEPEZZA (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-resupply-market-tepezzar-teprotumumab

[Solsen]

Nice. We have waited long for that announcement.

[StockBull]

Super - mon man kan forvente en ketchup effekt i Tepessa salget - tror det

[gdn55]

Forventet eller ej.I
ngen indflydelse på kursen? Jo den falder.